Patent details

EN | LT

LT - Use of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)- pyridin-4-yl]-thiazol-2-yl}-amide) in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target E

EN - Use of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)- pyridin-4-yl]-thiazol-2-yl}-amide) in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target E

Legal status

Patent not validated

Bibliographic data

Indications of the International Patent Classification (IPC)
(51)	INT.CL.	A61K 31/4439
		A61K 31/517
		A61K 39/395
		A61K 45/06
		A61P 35/00
		C07K 16/32
		A61K 39/00

European patent
(11)	Number of the document	2637661
(13)	Kind of document	T
(96)	European patent application number	11782111.6
	Date of filing the European patent application	2011-11-07
(97)	Date of publication of the European application	2013-09-18
(45)	Date of publication and mention of the grant of the patent	2017-12-20
(46)	Date of publication of the claims translation

PCT application
(86)	Number	PCT/EP2011/069522
	Date	2011-11-07

PCT application publication
(87)	Number	WO 2012/062694
	Date	2012-05-18

Priority applications
(30)	Number	Date	Country code
	411117 P	2010-11-08	US

Inventors
(72)	BRACHMANN, Saskia Maria, CH FRITSCH, Christine, CH MAIRA, Sauveur-Michel, CH SCHNELL, Christian René, CH GARCIA-ECHEVERRIA, Carlos, FR

Grantee
(73)	Novartis AG, Lichtstrasse 35, 4056 Basel, CH

Title
(54)	Use of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)- pyridin-4-yl]-thiazol-2-yl}-amide) in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target E
	Use of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)- pyridin-4-yl]-thiazol-2-yl}-amide) in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target E